Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Heart failure pathological mechanisms

Neurohumoral (extrinsic) compensation involves two major mechanisms (previously presented in Figure 6-7)—the sympathetic nervous system and the renin-angiotensin-aldosterone hormonal response—plus several others. Some of the pathologic as well as beneficial features of these compensatory responses are illustrated in Figure 13-2. The baroreceptor reflex appears to be reset, with a lower sensitivity to arterial pressure, in patients with heart failure. As a result, baroreceptor sensory input to the vasomotor center is reduced even at normal pressures sympathetic outflow is increased, and parasympathetic outflow is decreased. Increased sympathetic outflow causes tachycardia, increased cardiac contractility, and increased vascular tone. Vascular tone is further increased by angiotensin II and endothelin, a potent vasoconstrictor released by vascular endothelial cells. The result is a vicious cycle that is characteristic of heart failure (Figure 13-3). Vasoconstriction increases afterload, which further reduces ejection fraction and cardiac output. Neurohumoral antagonists and vasodilators... [Pg.303]

Furosemide is a widely used loop diuretic indicated for the treatment of different pathological conditions such as congestive heart failure, hepatic cirrhosis, and chronic renal failure. It has a narrow absorption window and mainly absorbed from the stomach and the upper part of the small intestine. Following administration of furosemide, the natriuretic effect rapidly disperses and is concealed before the next administration. This problematic aspect in furosemide therapy is mostly attributed to the natural homeostatic compensatory mechanisms. Lately, it has been demonstrated that the diuretic and natriuretic effects of furosemide can be significantly improved, following a continuous input (intravenous infusion) compared to immediate release DFs. Beside the narrow absorption window, this pharmacodynamic feature of the drug provides another rationale for the development of a GRDF for furosemide. [Pg.1858]

TABLE 18—1. Potential Pathologic Mechanisms of Diastolic Heart Failure... [Pg.359]


See other pages where Heart failure pathological mechanisms is mentioned: [Pg.352]    [Pg.202]    [Pg.918]    [Pg.919]    [Pg.61]    [Pg.505]    [Pg.106]    [Pg.291]    [Pg.145]    [Pg.265]    [Pg.12]    [Pg.1748]    [Pg.1284]    [Pg.419]    [Pg.299]    [Pg.307]    [Pg.561]    [Pg.562]    [Pg.236]    [Pg.147]    [Pg.152]    [Pg.14]    [Pg.156]    [Pg.147]    [Pg.346]    [Pg.255]    [Pg.362]    [Pg.597]    [Pg.1060]    [Pg.149]   
See also in sourсe #XX -- [ Pg.32 ]




SEARCH



Failure mechanics

Failure mechanisms

Mechanical failure

Pathologic

Pathological

© 2024 chempedia.info